Physician profile
Joseph Bessler
NPI 1306850276
$1,010.64
in general payments reported to CMS, 2019-2025
15 companies · $65.70 in 2025
The $65.70 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $241 · 2020: $68.86 · 2021: $72.61 · 2022: $89.09 · 2023: $430 · 2024: $42.69 · 2025: $65.70.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $539.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $538.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $252.17 | 2019-2025 | Farxiga, Fasenra |
| Abbott Laboratories | $170.38 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Abbvie INC. | $139.21 | 2023 | Vraylar |
| Glaxosmithkline, LLC. | $90.15 | 2023 | Arexvy, Shingrix, Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $62.16 | 2019 | |
| Novo Nordisk INC | $49.90 | 2022-2023 | Ozempic, Rybelsus |
| Pfizer INC. | $48.25 | 2019 | |
| Mylan Specialty L.P. | $42.82 | 2020-2022 | |
| Amarin Pharma, INC. | $33.68 | 2019-2021 | |
| Amgen INC. | $29.53 | 2019-2025 | Evenity |
| Otsuka America Pharmaceutical, INC. | $27.85 | 2022 | |
| Supernus Pharmaceuticals, INC. | $21.60 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.70 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.66 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $12.58 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Bessler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.